II. Indications
- Moderate to severe Acne Vulgaris
- Nodular, pustular, or cystic Acne Vulgaris
III. Management: Step 1 - Incorporate Moderate Acne Vulgaris Management
- See Topical Acne Vulgaris Management
- Continue Benzoyl Peroxide
- Continue Comedolytic (e.g. Retin A)
- Continue Topical Antibiotic (e.g. Cleocin T)
- May combine with Benzoyl Peroxide (e.g. Benzaclin)
- Consider Adjunctive Acne Vulgaris Management
IV. Management: Step 2 - Start Oral Antibiotics
-
General
- Do not expect an effect for 6 to 8 weeks
- Continue Antibiotic for minimum of 6 months
- Benzoyl Peroxide should be used with all Antibiotic regimens to prevent Antibiotic Resistance
- As with topical Antibiotic Resistance in acne, oral Antibiotic Resistance is also increasing
- Stop oral Antibiotics after acne improves (after 3-4 months) and continue topical agents
- First Line
- Doxycycline
- Dose: 50-100 mg once to twice daily
- May substitute Tetracycline 250 to 500 mg daily to twice daily
- Doxycycline replaces Tetracycline as first-line therapy as of the 2007 AAD guidelines
- Pregnancy Category D
- Erythromycin
- Dose: 1 g/day in 2-4 divided doses
- Increasing resistance decreases its efficacy (compared with Tetracyclines)
- Avoid in Acne Vulgaris, unless Tetracyclines are contraindicated
- Pregnancy Category B
- Doxycycline
- Alternative agents
- Indicated if first-line agents not tolerated
- Seysara (Tetracycline)
- Released in 2019 at $860/month compared with $30 for generic Doxycycline
- Difficult to see the benefit of an older, Generic Drug remarketed at 100x the original cost
- (2019) Presc Lett 26(3): 16
- Trimethoprim-Sulfamethoxazole (Bactrim, Septra)
- Dose: 160/800 (DS) twice daily
- Risk of sulfa Allergic Reaction
- Avoid in Acne Vulgaris, unless Tetracyclines and Macrolides are contraindicated
- Pregnancy Category C
- Trimethoprim
- Dose: 300 mg bid
- Avoid in Acne Vulgaris, unless Tetracyclines and Macrolides are contraindicated
- Pregnancy Category C
- Second Line
- Minocycline
- Dose: 50-200 mg/day in divided doses
- Considered first-line therapy by American Academy of Dermatology
- Risk of serious adverse effects (e.g. lupus-like reaction, Pseudotumor Cerebri)
- Pregnancy Category D
- Minocycline
V. Management: Step 3 - Maximal medical therapy (cystic or refractory acne)
-
Isotretinoin (Accutane)
- Consider in all patients with resistant or Cystic Acne (scarring)
- Dose
- Start 0.25 to 0.4 mg/kg/day (or 0.5 mg/kg/day if severe)
- Titrate to 1 mg/kg/day as tolerated after the first month
- Continue for 20 weeks
- Only qualified clinicians may prescribe (iPLEDGE)
- Adverse effects
- Extremely Teratogenic
- Monitor Triglycerides and Liver Function Tests and Complete Blood Count
- Major Depression and increased Suicidality
- Light and laser therapy
- Awaiting larger, more definitive studies as to efficacy
VI. References
- (2017) Presc Lett 24(12): 69
- Habif (2004) Dermatology, Mosby, p. 162-94
- Parker in Noble (2001) Primary Care p. 758-60
- Feldman (2004) Am Fam Physician 69:2123-56 [PubMed]
- Gollnick (2003) J Am Acad Dermatol 49:S1-37 [PubMed]
- James (2005) N Engl J Med 352(14):1463-72 [PubMed]
- Oge (2019) Am Fam Physician 100(8): 475-84 [PubMed]
- Strauss (2007) J Am Acad Dermatol 56(4): 651-63 [PubMed]
- Tan (2003) Am J Clin Dermatol 4:307-14 [PubMed]
- Titus (2012) Am Fam Physician 86(8): 734-40 [PubMed]